JP2006524185A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006524185A5 JP2006524185A5 JP2004571477A JP2004571477A JP2006524185A5 JP 2006524185 A5 JP2006524185 A5 JP 2006524185A5 JP 2004571477 A JP2004571477 A JP 2004571477A JP 2004571477 A JP2004571477 A JP 2004571477A JP 2006524185 A5 JP2006524185 A5 JP 2006524185A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- eye
- disorder
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 8
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 6
- 208000010412 Glaucoma Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000030533 eye disease Diseases 0.000 claims 5
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims 4
- 229960004194 lidocaine Drugs 0.000 claims 4
- 238000001356 surgical procedure Methods 0.000 claims 4
- 108030001720 Bontoxilysin Proteins 0.000 claims 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 3
- 208000001344 Macular Edema Diseases 0.000 claims 3
- 206010025415 Macular oedema Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 206010061323 Optic neuropathy Diseases 0.000 claims 3
- 208000017442 Retinal disease Diseases 0.000 claims 3
- 206010038903 Retinal vascular occlusion Diseases 0.000 claims 3
- 230000032683 aging Effects 0.000 claims 3
- 229940053031 botulinum toxin Drugs 0.000 claims 3
- 208000021921 corneal disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 229960002870 gabapentin Drugs 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 208000038015 macular disease Diseases 0.000 claims 3
- 201000010230 macular retinal edema Diseases 0.000 claims 3
- 210000003205 muscle Anatomy 0.000 claims 3
- 208000020911 optic nerve disease Diseases 0.000 claims 3
- 210000001685 thyroid gland Anatomy 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 101710138657 Neurotoxin Proteins 0.000 claims 2
- 206010030043 Ocular hypertension Diseases 0.000 claims 2
- 239000002537 cosmetic Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000002581 neurotoxin Substances 0.000 claims 2
- 231100000618 neurotoxin Toxicity 0.000 claims 2
- 210000001525 retina Anatomy 0.000 claims 2
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 238000002316 cosmetic surgery Methods 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 229960003299 ketamine Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960003404 mexiletine Drugs 0.000 claims 1
- 231100000302 myotoxic Toxicity 0.000 claims 1
- 230000003630 myotoxic effect Effects 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 239000004090 neuroprotective agent Substances 0.000 claims 1
- 239000002997 ophthalmic solution Substances 0.000 claims 1
- 229940054534 ophthalmic solution Drugs 0.000 claims 1
- 210000001328 optic nerve Anatomy 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 230000004262 retinal health Effects 0.000 claims 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims 1
- 229960003946 selegiline Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/421,956 US20040058313A1 (en) | 2002-04-24 | 2003-04-24 | Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
| PCT/US2003/038740 WO2004096183A1 (en) | 2003-04-24 | 2003-12-08 | Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006524185A JP2006524185A (ja) | 2006-10-26 |
| JP2006524185A5 true JP2006524185A5 (https=) | 2007-02-01 |
Family
ID=33415845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004571477A Pending JP2006524185A (ja) | 2003-04-24 | 2003-12-08 | 眼球及び眼周囲疾患を治療するための組成物、ターゲット、方法、及び装置 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20040058313A1 (https=) |
| EP (1) | EP1622589B1 (https=) |
| JP (1) | JP2006524185A (https=) |
| AU (1) | AU2003297684A1 (https=) |
| BR (1) | BR0318269A (https=) |
| CA (2) | CA2523363C (https=) |
| WO (1) | WO2004096183A1 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040170665A1 (en) * | 2000-06-02 | 2004-09-02 | Allergan, Inc. | Intravitreal botulinum toxin implant |
| ATE424187T1 (de) * | 2002-07-15 | 2009-03-15 | Alcon Inc | Bioerodierbare folie zur abgabe eines ophthalmischen arzneimittels |
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| US7220422B2 (en) * | 2003-05-20 | 2007-05-22 | Allergan, Inc. | Methods and compositions for treating eye disorders |
| US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US8673341B2 (en) * | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US20060073208A1 (en) | 2004-10-01 | 2006-04-06 | Allergan, Inc. | Cosmetic neurotoxin compositions and methods |
| EP1824496A4 (en) * | 2004-11-17 | 2008-07-16 | Joanne Mclaurin | COMPOSITIONS OF SCYLLO-INOSITOL DERIVATIVES AND METHOD FOR THE TREATMENT OF PROTEIN AGGREGATION DISORDERS |
| JP2007051090A (ja) * | 2005-08-18 | 2007-03-01 | Pharma Foods International Co Ltd | 卵白ペプチドを有効成分として含有する血流改善剤 |
| WO2007041855A1 (en) * | 2005-10-13 | 2007-04-19 | Waratah Pharmaceuticals, Inc. | Scyllo-inositol derivatives and their use in the treatment of diseases characterised by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence |
| US20070197452A1 (en) * | 2006-02-17 | 2007-08-23 | Mclaurin Joanne | Treatment of amyloid-related diseases |
| US20070197453A1 (en) * | 2006-02-17 | 2007-08-23 | Mclaurin Joanne | Compositions and methods for treatment of disorders of protein aggregation |
| CN103054837A (zh) * | 2006-03-09 | 2013-04-24 | 瓦拉塔药品公司 | 用于治疗蛋白积聚病症的环己烷多元醇制剂 |
| US20110028719A1 (en) * | 2006-05-19 | 2011-02-03 | Jacek Slon-Usakiewicz | Screening methods for amyloid beta modulators |
| US7759304B2 (en) | 2006-06-21 | 2010-07-20 | Regents Of The University Of Colorado | Targeting complement factor H for treatment of diseases |
| US20100173960A1 (en) * | 2006-09-21 | 2010-07-08 | Antonio Cruz | The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases |
| WO2008061373A1 (en) * | 2006-11-24 | 2008-05-29 | Waratah Pharmaceuticals Inc. | Combination treatments for alzheimer's disease and similar diseases |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| CA2683546A1 (en) * | 2007-04-12 | 2008-10-23 | Joanne Mclaurin | Use of cyclohexanehexol derivatives in the treatment of .alpha.-synucleinopathies |
| CA2683580A1 (en) * | 2007-04-12 | 2008-10-23 | Joanne Mclaurin | Treatment of amyotrophic lateral sclerosis |
| WO2008124930A1 (en) * | 2007-04-12 | 2008-10-23 | Joanne Mclaurin | Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases |
| JP2010523602A (ja) | 2007-04-12 | 2010-07-15 | ワラタ ファーマシューティカルズ， インコーポレイテッド | 眼疾患の治療におけるシクロヘキサンヘキソール誘導体の使用 |
| US7632848B1 (en) * | 2007-10-04 | 2009-12-15 | Alan Brown Scott | Medical treatment of muscles by exposure to anesthetic drugs |
| US8470337B2 (en) * | 2008-03-13 | 2013-06-25 | Allergan, Inc. | Therapeutic treatments using botulinum neurotoxin |
| WO2010036937A1 (en) * | 2008-09-27 | 2010-04-01 | Taraxos Inc. | Topical formulations for treatment of neuropathy |
| CA2740124A1 (en) * | 2008-10-09 | 2010-04-15 | Waratah Pharmaceuticals Inc. | Use of scyllo-inositols for the treatment of macular degeneration-related disorders |
| SG186397A1 (en) | 2010-06-22 | 2013-01-30 | Univ Colorado Regents | Antibodies to the c3d fragment of complement component 3 |
| US20120136011A1 (en) * | 2010-07-30 | 2012-05-31 | Allergan, Inc. | Compounds and methods for skin repair |
| US20120142684A1 (en) * | 2010-12-02 | 2012-06-07 | Allergan, Inc. | Compounds and methods for skin repair |
| AU2012238954A1 (en) * | 2011-04-07 | 2013-11-21 | Sensimed Sa | Device and method for detecting ophtalmic and/or brain diseases |
| CN105188733B (zh) | 2013-03-13 | 2020-05-08 | 建新公司 | 包含pdgf和vegf结合部分的融合蛋白及其使用方法 |
| RU2535115C1 (ru) | 2013-05-15 | 2014-12-10 | Бости Трейдинг Лтд | Фармацевтический состав, содержащий нейротоксин ботулина |
| JP6655074B2 (ja) | 2014-06-20 | 2020-02-26 | ジェネンテック， インコーポレイテッド | シャガシンに基づく足場組成物、方法及び使用 |
| JP7097070B2 (ja) | 2015-10-01 | 2022-07-07 | ゴレイニ インコーポレイテッド | クロライドチャネルの標的発現及びその使用方法 |
| US9918994B2 (en) | 2016-03-04 | 2018-03-20 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for muscle regeneration using prostaglandin E2 |
| US11096993B2 (en) | 2016-12-08 | 2021-08-24 | Gary E. Borodic | Method of treating macular degeneration using botulinum toxin-based pharmaceuticals |
| US11123411B2 (en) * | 2016-12-08 | 2021-09-21 | Gary E. Borodic | Method of treating macular degeneration using botulinum toxin-based pharmaceuticals |
| AU2018263853A1 (en) * | 2017-05-01 | 2019-11-14 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions and methods for treating ocular pathologies |
| WO2018227138A1 (en) | 2017-06-09 | 2018-12-13 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for preventing or treating muscle conditions |
| CN112972444B (zh) * | 2021-02-19 | 2022-07-26 | 中国医学科学院整形外科医院 | 美西律在制备治疗和/或预防面颈部皮肤皱纹的产品中的应用 |
| CN113288784B (zh) * | 2021-06-11 | 2023-03-31 | 中国人民解放军陆军军医大学第一附属医院 | 泪道冲洗收水装置 |
| KR20260039752A (ko) | 2023-07-13 | 2026-03-20 | 크리야 테라퓨틱스, 인크. | 보체 경로 억제제 융합체 및 그의 사용 방법 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3545260A (en) * | 1967-10-31 | 1970-12-08 | Technicon Corp | Means and method for detection of glaucoma |
| US3585849A (en) * | 1968-10-09 | 1971-06-22 | American Optical Corp | Method and apparatus for measuring intraocular pressure |
| US3724263A (en) * | 1970-09-29 | 1973-04-03 | Bio Optronics Inc | Electrical digital display tonometer |
| US3963019A (en) * | 1974-11-25 | 1976-06-15 | Quandt Robert S | Ocular testing method and apparatus |
| US4186184A (en) * | 1977-12-27 | 1980-01-29 | Alza Corporation | Selective administration of drug with ocular therapeutic system |
| US4305399A (en) * | 1978-10-31 | 1981-12-15 | The University Of Western Australia | Miniature transducer |
| CH633952A5 (fr) * | 1980-03-14 | 1983-01-14 | Grounauer Pierre Alain | Dispositif de mesure des potentiels electriques de l'oeil. |
| US4485820A (en) * | 1982-05-10 | 1984-12-04 | The Johns Hopkins University | Method and apparatus for the continuous monitoring of hemoglobin saturation in the blood of premature infants |
| US4734275A (en) * | 1983-08-19 | 1988-03-29 | Research Corporation | Anti-curare agents |
| JPS61321A (ja) * | 1984-06-12 | 1986-01-06 | 株式会社トプコン | 非接触式眼圧計 |
| US4629424A (en) * | 1984-08-30 | 1986-12-16 | Integrated Ionics, Inc. | Intraoral ambient sensing device |
| US4771792A (en) * | 1985-02-19 | 1988-09-20 | Seale Joseph B | Non-invasive determination of mechanical characteristics in the body |
| US4628938A (en) * | 1985-12-09 | 1986-12-16 | Lee David A | Continuous applanation tonometer |
| EP0242580B1 (en) * | 1986-03-13 | 1993-04-28 | The Trustees Of Columbia University In The City Of New York | Use of a, b and c prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma |
| JPS63267331A (ja) * | 1986-12-27 | 1988-11-04 | Tokyo Optical Co Ltd | 非接触式眼圧計 |
| US5076274A (en) * | 1987-02-18 | 1991-12-31 | Canon Kabushiki Kaisha | Non-contact tonometer |
| US5183044A (en) * | 1987-06-30 | 1993-02-02 | Kabushiki Kaisha Topcon | Noncontact type tonometer |
| US4922913A (en) * | 1987-11-12 | 1990-05-08 | Waters Jr George E | Intraocular pressure sensor |
| US4860755A (en) * | 1988-02-08 | 1989-08-29 | Erath-Young Instrument Company, Inc. | Differential pressure applanation tonometer |
| US5165409A (en) * | 1988-08-23 | 1992-11-24 | Coan William M | Tonometry apparatus |
| US5005577A (en) * | 1988-08-23 | 1991-04-09 | Frenkel Ronald E P | Intraocular lens pressure monitoring device |
| US4951671A (en) * | 1988-08-23 | 1990-08-28 | Coan William M | Tonometry apparatus |
| US5217015A (en) * | 1990-06-08 | 1993-06-08 | Kaye David B | Pressure sensing device having transducer overlying and deforming eye |
| US5109852A (en) * | 1990-06-08 | 1992-05-05 | Kaye David B | Method for sensing pressure in an object |
| US5342283A (en) * | 1990-08-13 | 1994-08-30 | Good Roger R | Endocurietherapy |
| US5148807A (en) * | 1990-08-28 | 1992-09-22 | Ohio State University | Non-contact tonometer |
| US5209231A (en) * | 1990-11-02 | 1993-05-11 | University Of Connecticut | Optical glucose sensor apparatus and method |
| US5295495A (en) * | 1991-05-13 | 1994-03-22 | The Australian National University | Glaucoma testing from observations of optokinetic nystagmus |
| US5251627A (en) * | 1991-06-27 | 1993-10-12 | Morris Donald E | Non-invasive measurement of eyeball pressure using vibration |
| US5179953A (en) * | 1991-08-27 | 1993-01-19 | Jermik Systems, Ltd. | Portable diurnal intraocular pressure recording system |
| US5972991A (en) * | 1992-09-21 | 1999-10-26 | Allergan | Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US5375595A (en) * | 1993-03-17 | 1994-12-27 | The Regents Of The University Of Calif. | Apparatus and method for non-contact, acoustic resonance determination of intraocular pressure |
| US6350781B1 (en) * | 1994-01-14 | 2002-02-26 | Lee Shahinia, Jr. | Method and analgesic preparations for sustained and extended corneal analgesia with subanesthetic concentrations of lidocaine |
| JPH11504944A (ja) * | 1995-11-06 | 1999-05-11 | サマーセット・ファーマシューティカルズ・インコーポレイテッド | セレギリンの舌下およびバッカル投与 |
| US6120460A (en) * | 1996-09-04 | 2000-09-19 | Abreu; Marcio Marc | Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions |
| US6544193B2 (en) * | 1996-09-04 | 2003-04-08 | Marcio Marc Abreu | Noninvasive measurement of chemical substances |
| US5830139A (en) * | 1996-09-04 | 1998-11-03 | Abreu; Marcio M. | Tonometer system for measuring intraocular pressure by applanation and/or indentation |
| US5922746A (en) * | 1997-03-27 | 1999-07-13 | Allergan | Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma |
| US6090847A (en) * | 1997-11-21 | 2000-07-18 | Allergan Sales, Inc. | EP2 -receptor agonists as neuroprotective agents for the eye |
| US6294583B1 (en) * | 1998-01-13 | 2001-09-25 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
| JP2002521332A (ja) * | 1998-07-21 | 2002-07-16 | メルク エンド カムパニー インコーポレーテッド | 高眼圧治療用眼薬組成物 |
| WO2000038667A2 (en) * | 1998-12-24 | 2000-07-06 | Alcon Laboratories, Inc. | Prostaglandin e agonists for treatment of glaucoma |
| ATE308510T1 (de) * | 1999-12-08 | 2005-11-15 | Warner Lambert Co | Inhibitore der verzweigte-aminosäure-abhängigen aminotransferase und deren verwendung in der behandlung der zuckerkranke retinopathie |
| US6306403B1 (en) * | 2000-06-14 | 2001-10-23 | Allergan Sales, Inc. | Method for treating parkinson's disease with a botulinum toxin |
-
2003
- 2003-04-24 US US10/421,956 patent/US20040058313A1/en not_active Abandoned
- 2003-12-08 AU AU2003297684A patent/AU2003297684A1/en not_active Abandoned
- 2003-12-08 BR BRPI0318269-0A patent/BR0318269A/pt not_active Application Discontinuation
- 2003-12-08 EP EP03816832.4A patent/EP1622589B1/en not_active Expired - Lifetime
- 2003-12-08 JP JP2004571477A patent/JP2006524185A/ja active Pending
- 2003-12-08 CA CA2523363A patent/CA2523363C/en not_active Expired - Fee Related
- 2003-12-08 CA CA2868648A patent/CA2868648A1/en not_active Abandoned
- 2003-12-08 WO PCT/US2003/038740 patent/WO2004096183A1/en not_active Ceased
-
2012
- 2012-07-20 US US13/554,349 patent/US20120282242A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006524185A5 (https=) | ||
| Yadav et al. | Glaucoma: Current treatment and impact of advanced drug delivery systems | |
| Casson | Medical therapy for glaucoma: A review | |
| Rowe et al. | Adverse side effects associated with latanoprost | |
| US6225348B1 (en) | Method of treating macular degeneration with a prostaglandin derivative | |
| Klein et al. | Central retinal artery occlusion without retrobulbar hemorrhage after retrobulbar anesthesia | |
| WO2010125416A1 (en) | Drug delivery to the anterior and posterior segments of the eye | |
| CA2807084C (en) | Preservative free brimonidine and timolol solutions | |
| JP2020535156A (ja) | 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物 | |
| JP2013535472A (ja) | 防腐剤無添加ビマトプロストおよびチモロール溶液 | |
| WO2017190142A1 (en) | Formulations and methods for reduction of intraocular pressure | |
| KR20180042348A (ko) | 안과 약물의 정량적 안와주위 적용 | |
| CN1382443A (zh) | 钠离子通道阻断剂在制备用于局部神经麻醉或镇痛的药物中的应用 | |
| JPH0723325B2 (ja) | 眼病用製剤 | |
| Khan et al. | Recent updates on drug delivery approaches for improved ocular delivery with an insight into nanostructured drug delivery carriers for anterior and posterior segment disorders | |
| JP2024506384A5 (https=) | ||
| DE60013126T2 (de) | Ophthalmische histamin-enthaltende zusammensetzungen und deren verwendung | |
| Heath | Neosynephrin hydrochloride: some uses and effects in ophthalmology | |
| Ueno et al. | Ocular pharmacology of drug release devices | |
| RU2199988C1 (ru) | Способ введения лекарственных веществ при лечении заболеваний заднего отрезка глаза | |
| CN107412211A (zh) | 氨基金刚烷胺单硝酸酯类化合物眼用组合物及其制剂和应用 | |
| RU2218896C1 (ru) | Способ лечения поствоспалительной буллезной кератопатии | |
| RU2735065C1 (ru) | Способ хирургического лечения первичной субкомпенсированной открытоугольной глаукомы с наличием токсико-аллергической реакции на гипотензивную терапию | |
| RU2766718C1 (ru) | Способ снижения внутриглазного давления после интравитреального введения ингибитора ангиогенеза Луцентиса при неоваскулярной глаукоме с внутриглазным давлением выше 30 мм рт.ст. на фоне пролиферативной диабетической и/или посттромботической ретинопатии | |
| RU2197931C1 (ru) | Способ хирургического лечения неоваскулярной глаукомы |